Dr. Reddy's Secures FDA Review for Abatacept Biologics License Application

MT Newswires Live00:29

Dr. Reddy's Laboratories (RDY) said Friday the US Food and Drug Administration has accepted for review its biologics license application for an IV infusion formulation of DRL_AB, a proposed biosimilar to Orencia, or abatacept.

Abatacept is a medication used to treat moderate to severe autoimmune diseases, including rheumatoid arthrities, psoriatic arthritis and juvenile idiopathic arthritis.

Following approval, the company said DRL_AB will be administered as an IV for infusion to treat adults with moderate to severely active rheumatoid arthritis, adults with active psoriatic arthritis, and individuals aged six years and older with moderate to severely active polyarticular juvenile idiopathic arthritis.

Price: 14.40, Change: +0.04, Percent Change: +0.31

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613295236?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-21 00:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613295236","market":"hk","top_or_hot":-1,"title":"Dr. Reddy's Secures FDA Review for Abatacept Biologics License Application","media":"MT Newswires Live","content":"<html><body><p> Dr. Reddy's Laboratories (RDY) said Friday the US Food and Drug Administration has accepted for review its biologics license application for an IV infusion formulation of DRL_AB, a proposed biosimilar to Orencia, or abatacept.</p><p>Abatacept is a medication used to treat moderate to severe autoimmune diseases, including rheumatoid arthrities, psoriatic arthritis and juvenile idiopathic arthritis.</p><p>Following approval, the company said DRL_AB will be administered as an IV for infusion to treat adults with moderate to severely active rheumatoid arthritis, adults with active psoriatic arthritis, and individuals aged six years and older with moderate to severely active polyarticular juvenile idiopathic arthritis.</p><p>Price: 14.40, Change: +0.04, Percent Change: +0.31</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dr. Reddy's Secures FDA Review for Abatacept Biologics License Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDr. Reddy's Secures FDA Review for Abatacept Biologics License Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-21 00:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Dr. Reddy's Laboratories (RDY) said Friday the US Food and Drug Administration has accepted for review its biologics license application for an IV infusion formulation of DRL_AB, a proposed biosimilar to Orencia, or abatacept.</p><p>Abatacept is a medication used to treat moderate to severe autoimmune diseases, including rheumatoid arthrities, psoriatic arthritis and juvenile idiopathic arthritis.</p><p>Following approval, the company said DRL_AB will be administered as an IV for infusion to treat adults with moderate to severely active rheumatoid arthritis, adults with active psoriatic arthritis, and individuals aged six years and older with moderate to severely active polyarticular juvenile idiopathic arthritis.</p><p>Price: 14.40, Change: +0.04, Percent Change: +0.31</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RDY.AU","symbol_name":"READYTECH HOLDINGS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2613295236","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613295236","pubTimestamp":1771604952,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dr. Reddy's Laboratories (RDY) said Friday the US Food and Drug Administration has accepted for review its biologics license application for an IV infusion formulation of DRL_AB, a proposed biosimilar","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RDY.AU":"READYTECH HOLDINGS LTD","LU0348744763.USD":"ALLIANZ ASIA PACIFIC INCOME \"A\" (USD) INC","BK4523":"印度概念","BK4557":"大麻股","RDY":"如瑞迪博士","BK4532":"文艺复兴科技持仓","BK4007":"制药","BK7016":"应用软件","BK4596":"哈里斯概念"},"translate_title":"Dr.Reddy's获得FDA对阿巴西普生物制品许可申请的审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RDY.AU":1,"RDY":1},"content_text":"Dr. Reddy's Laboratories (RDY) said Friday the US Food and Drug Administration has accepted for review its biologics license application for an IV infusion formulation of DRL_AB, a proposed biosimilar to Orencia, or abatacept.Abatacept is a medication used to treat moderate to severe autoimmune diseases, including rheumatoid arthrities, psoriatic arthritis and juvenile idiopathic arthritis.Following approval, the company said DRL_AB will be administered as an IV for infusion to treat adults with moderate to severely active rheumatoid arthritis, adults with active psoriatic arthritis, and individuals aged six years and older with moderate to severely active polyarticular juvenile idiopathic arthritis.Price: 14.40, Change: +0.04, Percent Change: +0.31","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613295236","isCrawlerRequest":true}